BioSpace News Archive

The U.S. FDA approved the use of Moderna’s and Janssen’s COVID-19 vaccines as a booster dose after their primary versions are completed.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

The Joint Corp. announced it will report its third quarter 2021 financial results on Thursday, November 4, 2021, after the market close.

Matinas BioPharma Holdings, Inc. today announced that it has dosed the first patient in a Phase 1 single ascending dose (SAD) pharmacokinetic study in healthy volunteers with MAT2501.

NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021.

Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will deliver a Company presentation and host one-on-one meetings during the BIO-Europe 2021 event, being held virtually October 25-28, 2021.

Nurix Therapeutics, Inc. today announced that Nurix’s president and chief executive officer Arthur T. Sands, M.D., Ph.D., and Nurix’s chief scientific officer Gwenn M. Hansen, Ph.D., will participate in several sessions of the 4th Annual Targeted Protein Degradation (TPD) Summit, which will be held virtually October 26-29, 2021.

BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), announced the first patient has been treated in an investigator-initiated, open-label Phase 2 study with lead asset plinabulin in combination with nivolumab + ipilimumab in patients with 3rd line recurrent small-cell lung cancer (SCLC) who failed checkpoint inhibitors and platinum-based chemotherapy.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 4, 2021.

Synthetic Biologics, Inc. today announced that enrollment has commenced and eight study participants were dosed in the Company’s Phase 1, placebo-controlled, multiple-ascending dose (MAD) clinical study of SYN-020 intestinal alkaline phosphatase (IAP).